12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PA32540: Phase III data

Top-line data from a pair of double-blind, U.S. Phase III trials in a total of 1,049 patients showed that once-daily oral PA32540 met the primary endpoint in both trials of reducing the cumulative incidence of gastric ulcers over 6 months vs. once-daily 325 mg enteric-coated aspirin. PA32540 also met the secondary endpoints...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >